title: Screening markers for chronic atrophic gastritis in Chiapas, Mexico.
abstract: Intestinal-type gastric adenocarcinomas usually are preceded by chronic atrophic gastritis. Studies of gastric cancer prevention often rely on identification of this condition. In a clinical trial, we sought to determine the best serological screening method for chronic atrophic gastritis and compared our findings to the published literature. Test characteristics of potential screening tests (antibodies to Helicobacter pyloni or CagA, elevated gastrin, low pepsinogen, increased age) alone or in combination were examined among consecutive subjects enrolled in a study of H. pylori and preneoplastic gastric lesions in Chiapas, Mexico; 70% had chronic atrophic gastritis. English-language articles concerning screening for chronic atrophic gastritis were also reviewed. Sensitivity for chronic atrophic gastritis was highest for antibodies to H. pylori (92%) or CagA, or gastrin levels >25 ng/l (both 83%). Specificity, however, was low for these tests (18, 41, and 22%, respectively). Pepsinogen levels were highly specific but insensitive markers of chronic atrophic gastritis (for pepsinogen I <25 microg/l, sensitivity was 6% and specificity was 100%; for pepsinogen I:pepsinogen II ratio <2.5, sensitivity was 14% and specificity was 96%). Combinations of markers did not improve test characteristics. Screening test characteristics from the literature varied widely and did not consistently identify a good screening strategy. In this study, CagA antibodies alone had the best combination of test characteristics for chronic atrophic gastritis screening. However, no screening test was both highly sensitive and highly specific for chronic atrophic gastritis.
authors.affiliation: Department of Health Research and Policy, Stanford University, California 94305, USA.
authors.forename: C
authors.initials: C
authors.lastname: Ley
authors.forename: A
authors.initials: A
authors.lastname: Mohar
authors.forename: J
authors.initials: J
authors.lastname: Guarner
authors.forename: R
authors.initials: R
authors.lastname: Herrera-Goepfert
authors.forename: L S
authors.initials: LS
authors.lastname: Figueroa
authors.forename: D
authors.initials: D
authors.lastname: Halperin
authors.forename: J
authors.initials: J
authors.lastname: Parsonnet
mesh_terms: D000328:Adult; D017677:Age Distribution; D000368:Aged; D015415:Biomarkers; D001707:Biopsy, Needle; D002908:Chronic Disease; D016001:Confidence Intervals; D005260:Female; D005755:Gastrins / Q000032:analysis*; D005757:Gastritis, Atrophic / Q000175:diagnosis* / Q000453:epidemiology; D005773:Gastroscopy / Q000379:methods; D016481:Helicobacter Infections / Q000175:diagnosis* / Q000453:epidemiology; D016480:Helicobacter pylori / Q000302:isolation & purification*; D006801:Humans; D015994:Incidence; D008297:Male; D008403:Mass Screening / Q000379:methods; D008800:Mexico / Q000453:epidemiology; D008875:Middle Aged; D020116:Pepsinogen A / Q000032:analysis*; D011237:Predictive Value of Tests; D012307:Risk Factors; D012680:Sensitivity and Specificity; D017678:Sex Distribution
chemical_list: D015415:Biomarkers; D005755:Gastrins; D020116:Pepsinogen A